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ABSTRACT
Background: Vitamin D is important to maternal, fetal, and infant health, but quality data on vitamin D status in low-
and middle-income countries and response to cholecalciferol supplementation in pregnancy are sparse.
Objective: We characterized vitamin D status and vitamin D metabolite change across pregnancy and in response to
cholecalciferol supplementation in rural Gambia.
Methods: This study was a secondary analysis of samples collected in a 4-arm trial of maternal nutritional
supplementation [iron folic acid (FeFol); multiple micronutrients (MMN); protein energy (PE) as lipid-based
supplement; PE + MMN]; MMN included 10 μg/d cholecalciferol. Plasma 25-hydroxycholecalciferol [25(OH)D3], 24,25-
dihydroxycholecalciferol [24,25(OH)2D3], and C3-epimer-25-hydroxycholecalciferol [3-epi-25(OH)D3] were measured by
LC-MS/MS in 863 women [aged 30 ± 7 y (mean ± SD)] in early pregnancy (presupplementation) and late pregnancy,
(gestational age 14 ± 3 and 30 ± 1 wk). Changes in 25(OH)D3 and vitamin D metabolite concentrations and associations
with pregnancy stage and maternal age and anthropometry were tested.
Results: Early pregnancy 25(OH)D3 concentration was 70 ± 15 nmol/L and increased according to pregnancy stage
(82 ± 18 and 87 ± 17 nmol/L in the FeFol and PE-arms) and to cholecalciferol supplementation (95 ± 19 and
90 ± 20 nmol/L in the MMN and PE + MMN-arms) (P < 0.0001). There was no difference between supplemented
groups. Early pregnancy 25(OH)D3 was positively associatedwithmaternal age and gestational age. Change in 25(OH)D3
was negatively associated with late pregnancy, but not early pregnancy, triceps skinfold thickness. The pattern of change
of 24,25(OH)2D3 mirrored that of 25(OH)D3 and appeared to flatten as pregnancy progressed, whereas 3-epi-25(OH)D3
concentration increased across pregnancy.
Conclusion: This study provides important data on the vitamin D status of a large cohort of healthy pregnant women
in rural Africa. Without supplementation, vitamin D status increased during pregnancy, demonstrating that pregnancy
stage should be considered when assessing vitamin D status. Nutritionally relevant cholecalciferol supplementation
further increased vitamin D status. These data are relevant to the development of fortification and supplementation
policies in pregnant women in West Africa. J Nutr 2019;00:1–13.
Keywords: Africa, nutritional requirements, pregnancy, vitamin D metabolism, cholecalciferol, season,
supplementation, lipid-based nutrient supplement
Introduction
Vitamin D is of relevance to maternal, fetal, and infant health
globally in relation to pregnancy-related complications (e.g.,
pre-eclampsia and gestational diabetes), preterm birth, and
infant-related outcomes (1, 2). In particular, meta-analyses of
observational data (3, 4) and vitamin D supplementation trials
(2, 5, 6) provide evidence for a beneficial effect of vitamin
D on birth weight and size and reduced risk of being born
small for gestational age. In relation to other health effects,
although some data provide evidence for a beneficial effect
of higher vitamin D status, these observations have yet to be
consistently borne out in supplementation trials, e.g., in relation
to gestational diabetes (7). Nevertheless, vitamin D deficiency in
pregnancy remains a concern and is of interest to international
organizations with the goal to optimize vitamin D status for
maternal and infant health (8, 9).
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Globally, 54% of pregnant women are estimated to have a
plasma/serum total 25-hydroxyvitamin [25(OH)D] concentra-
tion <50 nmol/L and 18% <25 nmol/L indicating a concerning
degree of vitamin D insufficiency and deficiency (10). More
recent reports have detailed vitamin D status in pregnant
women in Nigeria (11) and Tunisia (12), and indicated a
25(OH)D serum concentration of <50 nmol/L in 29% and
87%, respectively. However, it is evident that there is an
uneven global distribution of studies, with few in African and
Southeast Asian countries (13, 14). Authors of a recent report
concluded that 65% of low- and middle-income countries
had no published data that were suitable for inclusion in
their systematic literature review (15). Furthermore, reports of
vitamin D status from African countries are often of small
sample size and have often used nonstandardized methods
to measure vitamin D status. Therefore, there is a need for
better characterization of vitamin D status in African regions
particularly in pregnant women. Ethnic differences in vitamin
D status and vitamin D metabolism [e.g., related to vitamin D
binding protein (DBP) genotype, or parathyroid responsiveness]
may also potentially impact vitamin D requirements and
response to vitamin D supplementation in pregnancy, thus
studies in different ethnic populations are warranted and are
of importance in development of global nutrition policies (16).
Changes in 25(OH)D concentration, the primary marker of
vitamin D status, are not well characterized throughout preg-
nancy and data are conflicting (17–24). Lack of longitudinal
data, pregnancy-related physiological changes (e.g., changes
in plasma volume and protein concentrations), and seasonal
fluctuations lead to uncertainty over how vitamin D status may
change in pregnancy and consequently whether thresholds for
vitamin D deficiency are the same for nonpregnant and pregnant
adults. Such targets are important in the context of not only
ensuring vitamin D sufficiency in the mother, but also that of
the newborn (24).
Pregnancy-related changes in other vitamin D metabo-
lites, and whether they track changes in 25(OH)D, are not
well defined (24, 25). Changes in 24,25-dihydroxyvitamin
D [24,25(OH)2D] may provide information on the relative
activation of catabolic pathways (26, 27), including in preg-
nancy where CYP24A1 may be downregulated (28). Changes
in C3-epimer of 25-hydroxyvitamin D [3-epi-25(OH)D], a
metabolite that may contribute to vitamin D activity, are also
not certain. The reported contribution of either metabolite to
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vitamin D status will depend on the analytical methodology.
Chromatographic methods that do not resolve 3-epi-25(OH)D
from 25(OH)D and immunoassay methods for 25(OH)D that
cross-react with 24,25(OH)2D may lead to an overestimation
of vitamin D status (26, 29). In addition, some immunoassays
may underreport 25(OH)D because of the presence of high DBP
concentrations, as observed during pregnancy (30).
Vitamin D supplementation is generally effective in raising
plasma/serum 25(OH)D concentrations, including in pregnant
women (2, 24). However, there are few studies of vitamin
D supplementation at doses (≤10 μg/d) in line with recom-
mendations [e.g., from the Scientific Advisory Committee on
Nutrition (31) or the Institute of Medicine estimated average
requirement (32)] that may be more typical of population or
nationwide supplementation or fortification programs (9). In
pregnant women with known vitamin D deficiency, the WHO
recommended nutrient intake is 5 μg/d (200 IU) (33).
Therefore, in a secondary analysis of samples collected as
part of a randomized controlled trial of multiple-micronutrient
supplementation including vitamin D, and designed to enhance
infant immune development (34, 35), 25(OH)D and other
vitamin D metabolites were quantified by LC-MS/MS. Samples
were available from both early pregnancy (presupplementation)
and late pregnancy. The aims of this work were to 1)
characterize vitamin D status in a large pregnancy cohort in
sub-Saharan Africa,2) determine the impact on vitaminD status
of nutritionally relevant daily doses of supplemental vitamin D
(10 μg/d), and 3) describe vitamin D metabolite concentrations
across gestation.
Methods
Samples and data were collected as part of the ENID (Early Nutrition
and Infant Immune Development) trial (ISRCTN49285450) conducted
from MRC Keneba, MRC Unit The Gambia in the rural area of West
Kiang, a primarily subsistence farming community. At a latitude of
13◦North, UVB-containing sunshine is available year-round (15), and
most members of this predominantly Muslim community do not wear
clothes that prevent sunshine exposure to hands, arms, and face. The
Gambia has 2 distinct seasons, a “dry” season between November and
May characterized by hot, sunny days, and a “wet”season between June
and October with more cloud cover, higher humidity, and heavy rainfall.
During the wet season, farming activities are at their peak. A majority
of women undertake farming activities (36) and women continue these
throughout pregnancy (37). Further details about the region and its
demographics have been reported (38).
Study information
Full details of the ENID trial have been published (34, 35, 39) and
are summarized here in the context of the presented work. Women
aged 18–45 y, not severely anemic (hemoglobin <7 g/dL) or with HIV
infection, and premenopausal were recruited. The study was conducted
according to the guidelines laid down in the Declaration of Helsinki and
all procedures involving the participants were conducted as approved by
the joint Gambia Government-MRC Ethics Committee (Project number
SCC1126v2). Trained staff explained the study to participants, and
informed, written consent was obtained.
Women were visited and interviewed monthly by fieldworkers.
Pregnancy was initially indicated by human chorionic gonadotrophin
(hCG) testing (QuickVue™ One-Step hCG urine test, bioMerieux) and
then confirmed and gestational age assessed by ultrasound (Siemens
ACUSON Antares Ultrasound Imaging System, Siemens Medical
Solutions USA, Inc.). After confirmation of pregnancy, women were
randomly assigned to 1 of the 4 intervention arms, iron-folic acid (FeFol)
tablets, multiple micronutrient (MMN) tablets, a protein-energy (PE)
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lipid-nutrient supplement (LNS), or the PE supplement with multiple
micronutrients (PE + MMN). FeFol is the standard supplement advised
in pregnancy according to Gambian Government guidelines. MMN
arms included 10 μg/d (400 IU) of cholecalciferol (vitamin D3). A full
description of the contents of each supplement can be found inMoore et
al. (34).Compliance percentage was determined either through counting
the remaining tablets or estimation of remaining LNS supplement at the
end of each week (39). Participants were included in this analysis if a
plasma sample was available for vitaminD analysis either at recruitment
(“early pregnancy”and presupplementation) or at 30 weeks of gestation
(“late pregnancy”). Samples were collected throughout the year between
February 2010 and October 2013.
Data and sample collection
Participant data and anthropometry measurements were collected by
trained fieldworkers or midwives, and are described in full elsewhere
(34).Maternal blood samples were collected into lithium heparin blood
tubes from a forearm vein in the morning after an overnight fast. Plasma
was separated by centrifugation at at 1800× g for 10 min at 4◦C, stored
at −70◦C, and subsequently transported to the MRC Elsie Widdowson
Laboratory on dry ice and stored at −70◦C.
Sample analysis
The quantitation of plasma 25-hydroxyergocalciferol [25(OH)D2],
25-hydroxycholecalciferol [25(OH)D3], and C3-epimer of 25-
hydroxycholecalciferol [3-epi-25(OH)D3] was performed based
on a published LC-MS/MS method (40) with modifications and the
inclusion of 24,25-dihydroxycholecalciferol [24,25(OH)2D3] using a
Waters Acquity ultra-performance liquid chromatography instrument
and AB Sciex 5500QTrapmass spectrometer. The method used separate
isotope-labeled internal standards for each compound (for full details
see Supplemental Methods). The limit of quantification (LOQ) was
1.5 nmol/L for 25(OH)D2, 25(OH)D3, and 3-epi-25(OH)D3 analytes,
and 2.5 nmol/L for 24,25(OH)2D3. The MRC Elsie Widdowson
Laboratory is a member of the Vitamin D Standardization Program,
and quality assurance of the assay was performed as part of the
Vitamin D External Quality Assessment Scheme (www.deqas.org) and
performance assessed against NIST SRM 972a (for assay performance
see Supplemental Table 1).
Data analysis
Data analysis was performed with Stata 14.2 (StataCorp LLC).
Because only a few samples contained 25(OH)D2 above the LOQ,
all data analysis was performed with 25(OH)D3 only. Where vitamin
D metabolite concentrations were less than the LOQ, values were
computed by dividing the LOQ by the square root of 2 (41); assigned
values were 1.1 nmol/L and 1.8 nmol/L for 3-epi-25(OH)D3 and
24,25(OH)2D3, respectively. Normally distributed data are presented
as mean ± SD. Skewed data [i.e., 24,25(OH)2D3 and 3-epi-25(OH)D3
and their ratios] are presented as geometric mean and geometric mean
SD. Parity is presented as median and range.
Supplement group differences in both early and late pregnancy,
and differences between early and late pregnancy were tested by
ANOVA. Pairwise comparison of group means was tested post hoc
with Scheffé procedure. For skewed data, analysis was performed
using logged values. Pearson’s chi-square test was used for categorical
data and the Kruskal-Wallis H to test for equality of medians
(i.e., parity). Tests were not adjusted for weeks of pregnancy
because there was no difference between supplement groups in this
parameter.
The effect of season on 25(OH)D3 concentration was investigated
with the use of Fourier regression (42, 43), with pairs of sine and
cosine terms as independent predictors of 25(OH)D3. Annual data
were aggregated by the day of year on which the blood sample
was collected. The coefficient of cyclic variation summarized the
magnitude of the seasonal variation (42). In multivariate regression
models in early pregnancy, the sine and cosine terms were included to
allow other covariates to be interpreted independent of seasonal effects.
We investigated biologically plausible predictors of early pregnancy
25(OH)D3 concentration with use of linear regression. Significant
predictors of age and weeks of pregnancy were included in the
multivariate model,which also included Fourier terms to control for any
effect of time of year. To investigate predictors of attained 25(OH)D3,
both early pregnancy 25(OH)D3 concentration and supplementation
group were included in all models.
Vitamin D metabolite concentrations and their ratios were com-
pared between pregnancy stage and supplementation group using
ANOVA with Scheffé post hoc test. Percent 24,25(OH)2D3 and % 3-
epi-25(OH)D3 refer to the relative concentration of the metabolite to
25(OH)D3 concentration, that is 24,25(OH)2D3/25(OH)D3 ∗100.
The effect of gestational age on vitamin Dmetabolite concentrations
and the ratios of the metabolites to 25(OH)D were investigated using
a mixed linear model including weeks of pregnancy (fixed effect) and
participant ID (random effect). To describe the normal physiological
pattern in pregnancy, this analysis was performed in the FeFol group
only. Possible nonlinear associations were assessed by the inclusion of
a quadratic term (predictor∗predictor), but removed from the model if
not significant (P > 0.05). Metabolite concentrations below the LOQ
were excluded for this and for the following analysis; results with
these data are included in the Supplemental Material (Supplemental
Table 2).
Relations between vitamin D metabolites and their ratios against
25(OH)D3 concentration in early and late pregnancy were investigated
using linear regression. Quadratic terms were also tested but were
nonsignificant (P > 0.05). Data from the 4 groups were pooled
because there were no supplement group differences in 25(OH)D
and metabolite relations or ratios (investigated by the inclusion of
an interaction term between supplement group and the predictor
variable). Differences between early and late pregnancy in metabolite
relations were tested with the inclusion of interaction term between
time point (early/late pregnancy) and the continuous predictor
variable.
Results
Presupplementation, early pregnancy participant
characteristics, and vitamin D status
Participant characteristics and early pregnancy plasma
25(OH)D3 and vitamin D metabolite concentrations are shown
in Table 1. There were no differences between supplement
groups in age, weeks of pregnancy, anthropometric indices,
or vitamin D metabolite concentrations (P > 0.5). In early
pregnancy, the gestational age ranged between 7.0 and 20.8 wk.
The distribution of the month of sampling was not different
between supplementation groups (P = 1.0).
In early pregnancy, the mean plasma 25(OH)D3 concen-
tration was 70.2 ± 15.3 nmol/L. No woman had 25(OH)D3
<30 nmol/L. 25(OH)D2 was present above the LOQ in 50
(6%) samples in early pregnancy and in these women the
mean concentration was 1.8 ± 0.4 nmol/L, consistent with low
availability of vitamin D2 in this population.
Attained 25(OH)D3 concentration in late pregnancy
By late pregnancy, vitamin D status had significantly increased
in each of the 4 supplementation groups, that is in those receiv-
ing no vitamin D and those receiving micronutrient supplements
containing vitamin D (Table 1), with the shift to significantly
higher concentration distribution of 25(OH)D3 concentration
clearly visible in the vitamin D-supplemented groups (Figure 1).
Attained 25(OH)D3 concentration was significantly higher in
the two vitamin D-containing supplementation groups and in
the PE group compared to the FeFol group (Table 1), but there
was no difference between the MMN and PE + MMN groups.
Vitamin D supplementation in pregnant Gambians 3
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FIGURE 1 Distribution of plasma 25(OH)D3 concentrations by pregnancy stage and supplement group. (A) FeFol; (B) MMN; (C) PE; (D)
PE + MMN. FeFol, iron folic acid; MMN, multiple micronutrients; PE, protein energy; PE + MMN, protein energy with multiple micronutrients;
25(OH)D3, 25-hydroxycholecalciferol.
Expressed as the difference between early and late pregnancy,
the change in 25(OH)D3 concentration was not different
between MMN-containing groups nor between the non-MMN
containing groups (i.e., FeFol and PE groups) (Table 1). In the
FeFol group, the change was +10.8 ± 14.0 nmol/L and 20%
of participants had a decrease in 25(OH)D3 concentration. In
contrast, in the MMN only group, 5% of participants had a de-
crease in 25(OH)D3 concentration between early and late preg-
nancy. Vitamin D supplementation shifted the cohort distribu-
tion, reducing the percentage of participants in theMMN group
with 25(OH)D3 concentration <50 nmol/L to zero, but increas-
ing the proportion with a concentration>125 nmol/L (Figure 1;
Table 1).
Predictors of early pregnancy 25(OH)D3 concentration
There was a small but significant effect of time of year on
25(OH)D3 plasma concentration (Figure 2). The difference
between the modeled peak and nadir 25(OH)D3 concentration
was 6.4 nmol/L,with the peak in September and nadir inMarch.
The SD of this seasonal component was 2.2 nmol/L (coefficient
of cyclic variation= 4.4%) (after correction for age,weight, and
weeks of pregnancy). Investigated predictors of early pregnancy,
presupplementation, and 25(OH)D3 concentration are shown
in Table 2. 25(OH)D3 concentration was not associated
with maternal size or adiposity, but maternal age and weeks
of pregnancy positively predicted 25(OH)D3 concentration
(Figure 3). A multivariate model including age, weeks of
pregnancy, and Fourier terms to control for the effect of time
of year explained 11% of the variability in plasma 25(OH)D3,
with weeks of pregnancy predicting a 1.34 nmol/L higher
25(OH)D3 concentration for a 1-wk increase in gestational
stage (P < 0.0001) (Table 2).
Participant characteristics as predictors of attained
25(OH)D
Participant characteristics influencing 25(OH)D3 concentration
in late pregnancy were further investigated using a com-
bined model with presupplementation, baseline 25(OH)D3
concentration, and study arm as covariates. In these com-
bined models there were no significant interactions be-
tween predictor variables and supplementation group. At-
tained 25(OH)D3 concentration was positively associated with
compliance and weeks on supplementation, and negatively
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FIGURE 2 Seasonal variation in plasma 25(OH)D3 concentration in
early pregnancy. Observed (open circles) and Fourier regression mod-
eled seasonal variation (solid line) in plasma 25(OH)D3 concentration in
862 womenmeasured in early pregnancy. Day 1 constitutes 1 January
in each year. Boxes indicate dry (November toMay) or wet season (late
June to early October). 25(OH)D3, 25-hydroxycholecalciferol.
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TABLE 2 Predictors of early pregnancy plasma 25(OH)D3 concentration1
Univariate model Multivariate model
n β ± SE P β ± SE P
Age, y 863 0.27 ± 0.08 0.001 0.18 ± 0.07 0.015
Weight, kg 863 − 0.03 ± 0.05 0.6 — —
Height, cm 863 − 0.02 ± 0.09 0.8 — —
BMI, kg/m2 863 − 0.06 ± 0.15 0.7 — —
MUAC, cm 858 0.01 ± 0.16 1.0 — —
Triceps skinfold thickness, cm 858 − 0.04 ± 0.08 0.6 — —
Weeks of pregnancy 862 1.38 ± 0.15 <0.0001 1.34 ± 0.15 <0.0001
1Biologically plausible predictors of 25(OH)D3 concentration were tested and the multivariate model included Fourier terms to control for the effect of the time of year. Factors
were measured on the same day as blood sample collection. Parity was not included in the multivariate model because of a strong correlation with age. MUAC, midupper arm
circumference; 25(OH)D3, 25-hydroxycholecalciferol.
with late pregnancy triceps skinfold thickness (Table 3).
For every 1 cm greater triceps skinfold thickness in late
pregnancy, attained 25(OH)D3 concentration was 0.2 nmol/L
lower (P = 0.02). There were no associations with other
anthropometric indices measured in either early or late
pregnancy.
FIGURE 3 The relations between (A) weeks of pregnancy and
(B) maternal chronological age and plasma 25(OH)D3 concentra-
tion in early pregnancy. Open symbols are observed 25(OH)D3
concentration. Solid line is the modeled line. 25(OH)D3, 25-
hydroxycholecalciferol.
25(OH)D3 and vitamin D metabolites across gestation
We observed quadratic relations in both 25(OH)D3 and
24,25(OH)2D3 across gestation such that the positive linear in-
crease observed in early pregnancy appeared to flatten towards
late pregnancy. In contrast, 3-epi-25(OH)D3 concentration
increased as pregnancy progressed (Figure 4A, B, C). These ob-
servations were also reflected in metabolite ratios against weeks
of pregnancy (Figure 4D, E); the 25(OH)D3:24,25(OH)2D3
ratio was consistent across gestational age,whereas we observed
a significant negative relation between the 25(OH)D3:3-epi-
25(OH)D3 ratio and gestational age.
Vitamin D metabolites in early and late pregnancy
Plasma concentrations of 24,25(OH)2D3 are reported in
Table 4. There was a positive linear relation between
24,25(OH)2D3 and 25(OH)D3 concentration that was not
different between early and late pregnancy (P= 0.3 interaction)
(Figure 5A). In early pregnancy, there was a slight positive linear
relation between 25(OH)D3:24,25(OH)2D3 and 25(OH)D3
(P = 0.03), but this was not significantly different from the
nonsignificant relation observed in late pregnancy (P = 0.1
for interaction) (Figure 5C). We also performed the same
regression analyses using assigned values for 24,25(OH)2D3
concentrations that were below the LOQ (Supplemental
Table 2). In this scenario, slopes between 24,25(OH)2D3 and
25(OH)D3 were similar to those obtained using data above
the LOQ. However, in contrast to using data above the LOQ,
there were significant negative linear relations between the
ratio 25(OH)D3:24,25(OH)2D3 with 25(OH)D3 in both early
(β ± SE) (−0.082 ± 0.019, P < 0.0001) and late pregnancy
(−0.060 ± 0.013, P < 0.0001).
Plasma concentrations of 3-epi-25(OH)D3 are reported in
Table 4. In late pregnancy, the mean concentration and mean
%3-epi-25(OH)D3 were higher than in early pregnancy across
all supplementation groups (Table 4). The slopes of the signif-
icant positive linear relations between 25(OH)D3 and both 3-
epi-25(OH)D3 concentration and their ratios were not different
between early and late pregnancy (P > 0.4) (Figure 5B and D).
Discussion
We have characterized vitamin D status, response to sup-
plementation, and vitamin D metabolite concentrations in a
large cohort of pregnant women resident in rural Gambia.
This study generates important findings in relation to vitamin
D physiology in pregnancy. Firstly, we observed that during
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TABLE 3 Predictors of attained plasma 25(OH)D3 concentration in late pregnancy1
Univariate model2 Multivariate model2,3
n β ± SE P β ± SE P
Age, y 803 0.07 ± 0.08 0.4
Gestational age in late pregnancy, wk 803 − 0.77 ± 0.56 0.2 − 0.62 ± 0.55 0.3
Weight in early pregnancy, kg 803 − 0.06 ± 0.05 0.3 — —
Weight in late pregnancy, kg 802 − 0.06 ± 0.05 0.3 — —
Change in weight between early and late pregnancy, kg 802 − 0.03 ± 0.17 0.8 — —
MUAC in early pregnancy, cm 802 − 0.14 ± 0.16 0.4 — —
MUAC in late pregnancy, cm 803 − 0.25 ± 0.16 0.1 — —
Triceps skinfold thickness in early pregnancy, cm 802 − 0.11 ± 0.0 0.2 — —
Triceps skinfold thickness in late pregnancy, cm 803 − 0.21 ± 0.09 0.02 − 0.21 ± 0.09 0.02
Compliance, % 803 0.10 ± 0.04 0.02 0.10 ± 0.04 0.01
Weeks on supplement 798 0.97 ± 0.15 <0.0001 0.98 ± 0.15 <0.0001
1MUAC, midupper arm circumference; 25(OH)D3, 25-hydroxycholecalciferol.
2Early 25(OH)D3 concentration and supplementation group were included as covariates. Interactions between predictor variables and supplementation group were nonsignificant.
3n = 798.
pregnancy in women with relatively constant vitamin D
supply from cutaneous synthesis and generally good vitamin D
status, 25(OH)D3 concentration increased by 11 nmol/L across
pregnancy in the group not receiving supplemental vitamin D.
Weeks of pregnancy was a strong predictor of vitamin D status
and should therefore be considered in the interpretation of
studies of vitamin D status in pregnancy. Secondly, in groups
receiving 10 μg/d (400 IU/d) vitamin D3 within a micronutrient
supplement, there was an additional ∼11 nmol/L increase in
25(OH)D3 concentration across pregnancy. Thirdly, in women
not receiving vitamin D supplementation, 3-epi-25(OH)D3
concentration continued to increase across pregnancy suggest-
ing an independent effect of pregnancy on production of 3-epi-
25(OH)D3.
This is the largest study of vitamin D status in a pregnancy
cohort in Africa. The Gambia lies relatively close to the equator
at 13◦N and therefore receives year round UVB-containing sun-
shine (15). Although we detected some seasonality in vitamin D
Linear ± SE = 2.275 ± 0.688; P < 0.0001
Quadratic ± SE = −0.047 ± 0.016; P = 0.0030
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Early pregnancy: Slope ± SE = 0.054 ± 0.003; P < 0.0001 
Late pregnancy: Slope ± SE = 0.059 ± 0.003; P < 0.0001
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FIGURE 5 Relations in early and late pregnancy between 25(OH)D3 concentration and (A) plasma 24,25(OH)2D3 (early pregnancy: n= 580, late
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24,25(OH)2D3, 24,25-dihydroxycholecalciferol; 25(OH)D3, 25-hydroxycholecalciferol.
status, which followed predictions of UVB availability, the
effect was relatively modest and was equal to a difference of
∼6 nmol/L between the peak and nadir. To put this in context,
it is comparable to the magnitude of diurnal variation we have
observed in elderly people in The Gambia, the UK, and China
(43), and is considerably lower than seasonal variation observed
in pregnant women at higher latitudes (22, 44).
Vitamin D status was relatively high in this population with a
mean of∼70 nmol/L in early pregnancy; there was no vitamin D
deficiency [25(OH)D concentration <30 nmol/L] (31, 32). This
proportion is lower than some reports in pregnant women in
Africa (11, 12) and probably reflects the relatively high UVB
availability, skin exposure, and outdoor lifestyle in this rural
Gambian population (38). Themajority of circulating 25(OH)D
is derived from exposure to sunlight, including in The Gambia,
and the population has little or no access to fortified foods.
Mean 25(OH)D concentration at baseline was similar to other
cohorts from regions of similar latitude and supports the notion
of a physiological norm described previously (45). Although no
single population could be used to conclude what is normal,
and other local environmental factors and related metabolic
adaptations may need to be considered, this cohort provides
a unique data set that could be considered as representative
of the physiological norm for vitamin D metabolism in
pregnancy.
Weeks of pregnancy was a strong positive predictor of
25(OH)D3 concentration in early pregnancy and indicates that
this variable should be accurately determined and included in
the analysis of studies of vitamin D status during pregnancy.
The observed ∼11 nmol/L increase in 25(OH)D3 concentration
across pregnancy is equivalent to the increase expected with an
oral intake of ∼400 IU/d of vitamin D. Reported changes in
vitamin D status with gestation are inconsistent, partly because
of the large seasonal influence present in many studies, with
suggestions of increases (20, 46), (47), decreases (23), and no
change over pregnancy (17, 48). However, mean differences can
disguise large interindividual variation (17). The physiological
basis for the observed increase in 25(OH)D concentration may
relate to an increase in DBP during pregnancy. The change
we observed in 25(OH)D3 concentration up to ∼32 weeks
of pregnancy closely mirrors that observed in other studies
for DBP with an increase in early pregnancy followed by
flattening between ∼28 and 32 weeks of pregnancy (23).
This may imply that under circumstances where vitamin D
supply from UVB exposure is relatively unrestricted, as in
The Gambia, plasma 25(OH)D3 responds to an increase in
DBP concentration. Such a response cannot occur where
vitamin D supply is low or seasonal. This may indicate that
during pregnancy, when DBP increases, the % free 25(OH)D
is maintained, when permitted by a sufficiently high supply
of vitamin D. Recent data from a study in pregnant US
adolescents suggested a slight negative association between
% free 25(OH)D and 25(OH)D concentration, although free
25(OH)D was highly correlated with 25(OH)D and did better
predict associations with parathyroid hormone (49). In early
pregnancy, we also observed a significant positive association
between maternal age and 25(OH)D3 concentration. A similar,
albeit smaller effect, was also observed in a UK pregnancy
cohort measured in late pregnancy (50). In The Gambia, this
association may be related to secular trends in style of dress
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or time spent outside engaged in farming, gardening, or other
activities.
Vitamin D supplementation in this largely vitamin D-
replete population had a positive effect on vitamin D status
and reduced the proportion of women with both 25(OH)D3
concentration <50 nmol/L and the proportion with a decrease
in vitamin D status between early and late pregnancy. The
observed change in 25(OH)D3 concentration with daily doses
of 10 μg/d was consistent with the dose-response observed
in studies in other ethnic groups, including in pregnancy
(2, 24, 51). An advantage of this study was that we were
able to separate and demonstrate increases resulting from
pregnancy per se from those associated with supplementation.
A similar pregnancy-independent increase was also observed in
a recent vitamin D supplementation trial in Ireland; however,
seasonal changes in UVB supply were also influential (24),
whereas our observations are largely independent of season.
We demonstrate the positive effect on vitamin D status of a
nutritionally relevant vitamin D supplement dose that is in line
with amounts typically used in supplementation programs or
that are obtainable through fortification.These data are relevant
to the debate around the design of vitamin D supplementation
trials and ethical concerns over the use of true placebo or active
placebo (where the control group consists of a “low” dose
supplementation) as the comparative arm, as commonly applied
in randomized controlled trials of pharmacological agents
(52, 53).
Dietary reference values for pregnant women are typically
the same or based on an incremental increase over the
recommendations for nonpregnant adults (9, 24). The reasons
for this are attributable to the lack of data on pregnancy-related
health outcomes, uncertainty over whether there is a metabolic
increase in vitamin D requirements, and, until recently (24),
a lack of data on the dose-response in pregnancy. The WHO
recommendation is that sunlight exposure is the most important
source of vitamin D and that the evidence does not support
the use of supplemental vitamin D in pregnancy, with the
exception of where there is confirmed vitamin D deficiency
(33). Normal physiological changes in vitamin D status in
pregnancy have been difficult to quantify partly because of the
seasonal variation in vitamin D supply exhibited in Europe
and the United States, where the majority of pregnancy
studies have been performed. More recent studies have used
seasonal correction to model 25(OH)D change in pregnancy,
but data remain conflicting on the gestational-related change
in 25(OH)D concentration (19, 22). In a study using stable
isotope-labeled 25(OH)D, we have previously shown that
25(OH)D expenditure was not different between pregnant and
nonpregnant women (21). Together with the data from the
current study and based on the study of vitamin D status,
this suggests that in this population, metabolically, pregnant
women may not require more vitamin D than nonpregnant
women and that metabolic adaptations or efficiencies are able to
maintain vitamin D status where vitamin D supply is adequate
and constant. Further confirmatory studies in other populations
with for example, different vitamin D status, different DBP
polymorphisms, or levels of adiposity, are required. However,
this finding does not remove the need to ensure that all pregnant
women are vitamin D sufficient. As discussed above, recent
meta-analyses provide evidence for a beneficial effect of vitamin
D on birth weight and size. Furthermore, recent data suggest
that higher vitamin D intakes for pregnant women may be
needed to ensure a plasma/serum 25(OH)D3 concentration in
cord blood of >50 nmol/L (24).
Vitamin D supplementation in our study increased the pro-
portion of women with 25(OH)D3 concentration>125 nmol/L,
the lower end of the range (125–150 nmol/L) at which the
Institute of Medicine reported as a cause for concern (while
also recognizing the lack of data) (32). As reviewed elsewhere
(2), maternal supplementation studies report few adverse effects
(e.g., cases of hypercalcemia) (51, 54–56). However, these
reports in pregnancy do not negate the concerns around higher
vitamin D doses in relation to increased risks of falls and
fractures nor with individuals within a population with medical
disorders that may predispose to hypercalcemia (31), and the
effects on fetal development are unknown.
Evidence suggests a negative association between response
to vitamin D supplementation and measures of adiposity in
both pregnant and nonpregnant women (50, 57). We did not
find a relation between vitamin D status and BMI. This may
be explained by the relatively low and narrow range of BMI
observed in this population. Furthermore, as discussed below,
assessment of adiposity during pregnancy is challenging. In our
study, we found a negative association between late-pregnancy
triceps skinfold thickness and 25(OH)D3 concentration, after
adjustment for other factors. The relation with skinfold thick-
ness may only have become apparent in late pregnancy after oral
vitamin D because of differences in vitamin D transport. The
tissue distribution of oral vitamin D that is initially transported
by chylomicrons and lipoproteins may be different to that of
cutaneously synthesized vitamin D transported by DBP (57).
Population body composition may need to be considered when
designing supplementation programs in different populations.
Changes in body fat mass are more challenging to measure
in pregnancy than in nonpregnant adults. However, the use
of triceps skinfold thickness has been found to be a good
estimate of fat mass in the absence of more invasive, advanced
methods (58). We observed large interindividual variation in
change of 25(OH)D3 concentration over pregnancy and in
response to supplementation (2). The factors that influence this
variation remain to be elucidated but may relate to differences
in metabolism (because of genetic polymorphisms, other dietary
or hormonal factors, or differences in lifestyle). We did not
measure dietary calcium intake in this cohort. However, studies
in this population indicate that calcium intakes are generally
low (<400 mg/d) by international standards and do not change
in pregnancy (21). Other studies in The Gambia (59) and in
an Irish population (60) indicated that vitamin D use was not
affected by low calcium intake.
In early pregnancy, vitamin D metabolites, 24,25(OH)2D3
and 3-epi-25(OH)D3, increased with rising 25(OH)D3 con-
centration. For 24,25(OH)2D3, the increase was followed
by a flattening that closely mirrored that of 25(OH)D3. In
contrast, 3-epi-25(OH)D3 concentration continued to rise, an
observation that was reflected when its ratio was plotted against
weeks of pregnancy. This is consistent with recent work that
reported an increase in 3-epi-25(OH)D3 as pregnancy pro-
gressed (24, 61). As a percentage of 25(OH)D3 concentration,
the 3-epi-25(OH)D3 results are similar to those estimated from
the results from some studies (24) but higher than others
(61). The source and biological significance of the relatively
higher 3-epi-25(OH)D3 concentration in pregnancy, as well
as in neonates (61), are unknown (62). It is suggested that
production of 24,25(OH)2D3 may be suppressed at lower
25(OH)D3 concentrations (<∼25 nmol/L) (63), and Best et al.
reported that 24,25(OH)2D3 concentration in pregnancy was
related to both gestational stage and 25(OH)D3 concentration
(25). Our results suggest that 24,25(OH)2D3 may be more
10 Jones et al.
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related to 25(OH)D3 because the ratio across gestation did
not change. The 24,25(OH)2D3:25(OH)D3 ratio is lower than
reported in studies of nonpregnant adults (26), but consistent
with a previous report of pregnant women. Lower relative
24,25(OH)2D may be related to a downregulation of the
CY24A1 enzyme in pregnancy (24).
An advantage of this study was our ability to determine
changes in vitamin D status across pregnancy in a relatively
large number of individuals where the effect of season was
small. In contrast to some studies, the use of an LC-
MS/MS method that fully resolved and quantified 25(OH)D2,
25(OH)D3, 3-epi-25(OH)D3, and 24,25(OH)2D3 provides
confidence over the change in vitamin D status over pregnancy
as well as providing data on vitamin D metabolite changes over
pregnancy.
This study was limited by factors related to the original
study design. The latest sample collected during pregnancy
was around 30 weeks of gestation, thus we are not able to
infer changes in vitamin D status nearer delivery. We did not
collect dietary data on vitamin D but vitamin D-containing
foods or supplements are not considered to be significant
sources of vitamin D in this tropical, rural, largely subsistence-
farming community and thus the changes we observed over
pregnancy can be interpreted in the context of a stable
vitamin D supply from UVB-containing sunshine. We did not
include variables related to income, education, or other social
economic scores. However, other reports of this cohort report
limited heterogeneity in these factors (64, 65). The limit of
quantification of our LC-MS/MS method for 24,25(OH)2D3
was higher than in some other studies (25) and meant we were
not able to include all participants in the 24,25(OH)2D3 models.
In conclusion, this study provides an accurate assessment of
vitamin D status in a pregnancy cohort in rural Gambia and
contributes to data on vitamin D status in low- and middle-
income countries that are scarce and may be limited by sample
size and the choice of vitamin D assay. Importantly, this study
provides information on 25(OH)D and vitamin D metabolite
response to pregnancy and vitamin D supplementation when
vitamin D supply is stable from year-round high UVB
availability. The generalizability of these findings to other
populations requires further study in different groups. The
potential relevance of nutritionally relevant doses (10 μg/d)
and their impact in vitamin D supplementation trials and
relevance to the development of vitamin D fortification and
supplementation policies in pregnant women are highlighted.
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